Two Epinephrine Strengths During Endoscopic Removal of Stomach Growths
Compares two epinephrine strengths injected during endoscopic stomach tissue removal in adults.
Plain-language title generated from the registry record
Registry title: Epinephrine 1:100,000 Versus 1:500,000 During Gastric Endoscopic Submucosal Dissection
Key facts
- Where
- Guimarães, PortugalSee the site
Where in Portugal
- Unidade Local de Saúde do Alto AveGuimarães, PortugalTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Unidade Local de Saúde do Alto Ave, EPE
- Trial code
- NCT07920068
- Record updated
- 5 November 2026
- Original description
This prospective, randomized, single-center trial compares two epinephrine concentrations (1:100,000 and 1:500,000) in the submucosal injection solution used during gastric endoscopic submucosal dissection. The study evaluates whether the lower epinephrine concentration can maintain procedural efficiency while reducing epinephrine dose, without compromising hemostatic efficacy or safety. A total of 100 participants are planned.Read full original descriptionShow less
Optimal Epinephrine Concentration in Gastric Endoscopic Submucosal Dissection: A Prospective Randomized Trial
This prospective, randomized, single-center trial compares two epinephrine concentrations (1:100,000 and 1:500,000) in the submucosal injection solution used during gastric endoscopic submucosal dissection. The study evaluates whether the lower epinephrine concentration can maintain procedural efficiency while reducing epinephrine dose, without compromising hemostatic efficacy or safety. A total of 100 participants are planned.
Inclusion: Age 18 years or older; Patients scheduled to undergo gastric endoscopic submucosal dissection (ESD) for a dysplastic or neoplastic gastric lesion; Ability to provide written informed consent for participation in the study.
Exclusion: Any clinical condition considered by the investigator to preclude safe participation in the study; Refusal or inability to provide informed consent; Contraindication to any component of the submucosal injection solution used in the study.